{"title":"Lipogenic stearoyl-CoA desaturase-1 (SCD1) targeted virtual screening for chemical inhibitors: molecular docking / dynamics simulation and in vitro assessment of anti-NAFLD efficacy","link":"http://pubs.rsc.org/en/Content/ArticleLanding/2024/RA/D4RA06037G","date":null,"content":"<div><p><img src=\"/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/image/GA?id=D4RA06037G\" /></p></div><div><i><b>RSC Adv.</b></i>, 2024, <b>14</b>,31797-31808<br /><b>DOI</b>: 10.1039/D4RA06037G, Paper</div><div><img alt=\"Open Access\" src=\"http://sod-a.rsc-cdn.org/pubs.rsc-uat.org/content/NewImages/open_access_blue.png\" /> Open Access</div><div><a href=\"http://creativecommons.org/licenses/by-nc/3.0/\" target=\"_blank\"> <img src=\"http://sod-a.rsc-cdn.org/pubs.rsc-uat.org/content/NewImages/CCBY-NC.png\" alt=\"Creative Commons Licence\" /></a>Â  This article is licensed under a <a href=\"http://creativecommons.org/licenses/by-nc/3.0/\" target=\"_blank\">Creative Commons Attribution-NonCommercial 3.0 Unported Licence.</a></div><div>Sonakshi Puri, Shivani Kirad, Mohammed Muzaffar-Ur-Rehman, Sumit Kumar Mandal, Pankaj Kumar Sharma, Murugesan Sankaranarayanan, P. R. Deepa<br />HTVS revealed Montelukast as top-scoring SCD1 inhibitor. Reduction in hepatic fat accumulation and oxidative stress by Montelukast indicates its pharmacological potential in metabolic disorders.<br />The content of this RSS Feed (c) The Royal Society of Chemistry</div>","author":"","siteTitle":"RSC - RSC Adv. latest articles","siteHash":"da3e282678330308414c63a405ade89dd3738fcce2936ca8a2fe3a6d7e967d99","entryHash":"653245e23cef968cfb2a71256804c5bf59cf7cf361475a519e85b01cb8136f76","category":"Environment"}